Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-Dose Convalescent Plasma for Treatment of Severe COVID-19.
De Santis GC, Oliveira LC, Garibaldi PMM, Almado CEL, Croda J, Arcanjo GGA, Oliveira ÉAF, Tonacio AC, Langhi DM Jr, Bordin JO, Gilio RN, Palma LC, Santos EV, Haddad SK, Prado BPA Jr, Pontelli MC, Gomes R, Miranda CH, Auxiliadora Martins M, Covas DT, Arruda E, Fonseca BAL, Calado RT. De Santis GC, et al. Emerg Infect Dis. 2022 Mar;28(3):548-555. doi: 10.3201/eid2803.212299. Epub 2022 Jan 26. Emerg Infect Dis. 2022. PMID: 35081022 Free PMC article. Clinical Trial.
Compassionate use of cell products.
de Santis GC, Ubiali EM, Covas DT. de Santis GC, et al. Rev Bras Hematol Hemoter. 2013;35(2):144-5. doi: 10.5581/1516-8484.20130036. Rev Bras Hematol Hemoter. 2013. PMID: 23741193 Free PMC article. No abstract available.
Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19.
De Santis GC, Mendrone A, Langhi D Jr, Covas DT, Fabron A Jr, Cortez AJP, Dinardo CL, Ubiali EMA, Marques JFC Jr, Bordin JO, Rugani MA. De Santis GC, et al. Hematol Transfus Cell Ther. 2021 Apr-Jun;43(2):212-213. doi: 10.1016/j.htct.2021.03.001. Epub 2021 Mar 20. Hematol Transfus Cell Ther. 2021. PMID: 33778377 Free PMC article. No abstract available.
Histo-blood group A is a risk factor for severe COVID-19.
Garibaldi PMM, Oliveira LC, da Fonseca BA, Auxiliadora-Martins M, Miranda CH, Almado CEL, Langhi DM, Gilio RN, Palma LC, Gomes BBM, Bottura C, Barrientto LC, Donadel CD, Calado RT, De Santis GC. Garibaldi PMM, et al. Among authors: de santis gc. Transfus Med. 2022 Jun;32(3):248-251. doi: 10.1111/tme.12796. Epub 2021 Jun 3. Transfus Med. 2022. PMID: 34085363 Free PMC article.
SARS-COV-2: is it a risk for blood transfusion?
Langhi DM, de Souza RC, Barros M, De Santis GC, Kashima SH, Bordin JO. Langhi DM, et al. Among authors: de souza rc, de santis gc. Hematol Transfus Cell Ther. 2022 Jan-Mar;44(1):100-103. doi: 10.1016/j.htct.2021.08.001. Epub 2021 Sep 1. Hematol Transfus Cell Ther. 2022. PMID: 34485826 Free PMC article. No abstract available.
Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI).
Song ATW, Rocha V, Mendrone-Júnior A, Calado RT, De Santis GC, Benites BD, Costa-Lima C, Vargas T, Marques LS, Fernandes JC, Breda FC, Wendel S, Fachini R, Rizzo LV, Kutner JM, Avelino-Silva VI, Machado RRG, Durigon EL, Chevret S, Kallas EG. Song ATW, et al. Among authors: de santis gc. Lancet Reg Health Am. 2022 Jun;10:100216. doi: 10.1016/j.lana.2022.100216. Epub 2022 Mar 15. Lancet Reg Health Am. 2022. PMID: 35308034 Free PMC article.
54 results